Network origin in Hui Yu Xu first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Medical Specialties | 13 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Hui Yu Xu via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Polymer Technology Systems, Inc.
 Polymer Technology Systems, Inc. Medical SpecialtiesHealth Technology Polymer Technology Systems, Inc. develops, manufactures and sells hand-held diagnostic devices. It is an point-of-care diagnostics solutions provider that partners with patients and healthcare professionals to provide the right information at the right time to make the right decisions. The company was founded in 1992 and is headquartered in Indianapolis, IN. | Medical Specialties | Chairman | |
| University of Pennsylvania | College/University | Undergraduate Degree | |
Trividia Health, Inc.
 Trividia Health, Inc. Medical SpecialtiesHealth Technology Trividia Health, Inc. develops, manufactures and markets diabetes monitoring and management products. It supplies blood glucose monitoring systems, cobranded under the TRUE name, to pharmacies, distributors and mail service providers. The company was founded by George H. Holley in 1985 and is headquartered in Fort Lauderdale, FL. | Medical Specialties | Chairman | |
| Dominican University of California | College/University | Undergraduate Degree | |
| National Chengchi University | College/University | Undergraduate Degree | |
| China Europe International Business School | College/University | Masters Business Admin | |
| Hunan University | College/University | Undergraduate Degree | |
| Beijing Technology & Business University | College/University | Undergraduate Degree | |
| Central South University | College/University | Doctorate Degree | |
| Capital Medical University | College/University | Corporate Officer/Principal | |
| PBC School of Finance Tsinghua University | College/University | Masters Business Admin | |
| IMPROVE MEDICAL INSTRUMENTS CO., LTD. | Medical Specialties | Director/Board Member | |
| DIRUI INDUSTRIAL CO.,LTD. | Medical Specialties | Director/Board Member | |
| BOAI NKY MEDICAL HOLDINGS LTD. | Chemicals: Specialty | Director/Board Member | |
| Hunan University of Finance & Economics | College/University | Undergraduate Degree | |
| BEIJING BOHUI INNOVATION BIOTECHNOLOGY GROUP CO., LTD. | Biotechnology | Director/Board Member | |
Hunan Wispring Education Development Foundation
 Hunan Wispring Education Development Foundation Investment Trusts/Mutual FundsMiscellaneous Hunan Wispring Education Development Foundation operates as an educational non-public fundraising foundation. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
| Hunan Medical Device Industry Association | Director/Board Member | ||
| Xiangya School of Medicine | College/University | Graduate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin | |
| Tokyo Medical University | College/University | Doctorate Degree | |
Shanghai Baio Technology Co., Ltd.
 Shanghai Baio Technology Co., Ltd. Medical SpecialtiesHealth Technology Shanghai BaiO Technology Co., Ltd. engages in the development, production and sale of invitro diagnostic reagents, instruments, consumables and genetic testing products. Its products include Class III in vitro diagnostic reagents, Class II medical devices, Class I in vitro diagnostic reagents and other products. The company was founded on November 13, 2000 and is headquartered in Shanghai, China. | Medical Specialties | Director/Board Member | |
Shenzhen Xinnuo Health Industry Investment Co., Ltd.
 Shenzhen Xinnuo Health Industry Investment Co., Ltd. Financial ConglomeratesFinance Shenzhen Xinnuo Health Industry Investment Co. Ltd. engages in the provision of investment services with interests in medical and health industries. Its business activities include investment in biotechnology, biotechnology research and development, health management and consulting, and investment management and advisory services. The company was founded on April 27, 2015 and is headquartered in Shenzhen, China. | Financial Conglomerates | Chief Executive Officer | |
| Xi'an University of Electronic Science & Technology | College/University | Undergraduate Degree | |
| GETEIN BIOTECH, INC | Biotechnology | Director/Board Member | |
| Business School of Hunan University | College/University | Masters Business Admin | |
Xiamen Zeesan Biotech Co., Ltd.
 Xiamen Zeesan Biotech Co., Ltd. Medical/Nursing ServicesHealth Services Xiamen Zeesan Biotech Co., Ltd. engages in the research and development, production, and sales of molecular diagnostic technology, molecular diagnostic reagents, and molecular diagnostic instruments. It specializes in molecular diagnostic reagent products and molecular diagnostic instrument products, provides the basis for disease screening and diagnosis, drug selection and efficacy monitoring of infectious diseases including respiratory disease and human papillomavirus infection, hematologic oncology, personalized medicine and genetic diseases. The company was founded on June 12, 2010 and is headquartered in Xiamen, China. | Medical/Nursing Services | Director/Board Member | |
Denovo Biopharma Co., Ltd.
 Denovo Biopharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Denovo Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Beijing, China. Denovo Biopharma uses novel biomarker approaches to execute efficient clinical trials in targeted patient populations to optimize the probability of successful trials. The Chinese company has eight late clinical stage drugs in its pipeline addressing major unmet medical needs in oncology and CNS diseases, most of which are first-in-class drugs with rights. Denovo Biopharma seeks to discover genomic biomarkers correlated with patients' responses to drug candidates retrospectively. The company designs and executes efficient clinical trials in targeted patient populations to optimize the probability of a successful trial. Denovo Biopharma is enrolling patients in a phase 3 clinical trial for its lead asset db102 (enzastaurin) in diffuse large B-cell lymphoma (DLBCL) and will start a phase 2b study in glioblastoma (GBM). The company has four additional late-stage programs targeting major unmet needs\: db103 for schizophrenia, db104 for depression, db105 for Alzheimer's disease, and db106 for acute myeloid leukemia (AML). Denovo Biopharma is a next-generation biomarker partner to personalize your drug. The company was founded in 2012 by Wen Luo. | Pharmaceuticals: Major | Director of Finance/CFO | |
| SUZHOU BASECARE MEDICAL CORPORATION LIMITED | Medical Specialties | Director/Board Member | |
| Suzhou Niuai Health Technology Co. , Ltd. | Director/Board Member | ||
| Guangzhou Yangpu Medical Technology Co. Ltd. | Director/Board Member | ||
| Nanjing Jidan Biotechnology Co. Ltd. | Director/Board Member | ||
| GUANGZHOU WONDFO BIOTECH CO.,LTD | Biotechnology | Director/Board Member | |
| Guanghua School of Management | College/University | Masters Business Admin |
Statistics
International
| China | 28 |
| United States | 6 |
| Taiwan | 2 |
Sectoral
| Consumer Services | 17 |
| Health Technology | 11 |
| Process Industries | 2 |
| Miscellaneous | 2 |
| Finance | 2 |
Operational
| Director/Board Member | 25 |
| Independent Dir/Board Member | 13 |
| Undergraduate Degree | 7 |
| Chairman | 5 |
| Masters Business Admin | 5 |
Most connected contacts
| Insiders | |
|---|---|
| Xi Xiong Kang | 15 |
| Shao Bo Li | 9 |
| Ji Zheng Chen | 4 |
| Hui Li | 3 |
| Shi Min Wang | 2 |
| Hong Yuan | 2 |
| Hong Jing Che | 2 |
| Bo Shen Ou Yang | 2 |
| Shao Bo Huang | 2 |
| Xin Yi Li | 2 |
| Chun Geng Chen | 2 |
- Stock Market
- Insiders
- Hui Yu Xu
- Company connections
